Skip to contentP
Petros Pharmaceuticals, Inc.
P
PTPIPetros Pharmaceuticals, Inc. Q1 2026 · 10-Q
Revenue—
Net Income-$987.04K-$987.04KN/M vs Q1 2025 EPS Diluted-$0.03-$0.03N/M vs Q1 2025 Operating Income-$1,027,179N/M Operating Cash Flow-$784,272N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Petros Pharmaceuticals, Inc. · CIK 1815903 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 13, 2026 · 43 d after period end